

Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Grazoprevir / Elbasvir Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification


Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Short-term (acute) aquatic hazard : Category 3

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms : 

Signal word : Warning

Hazard statements : H402 Harmful to aquatic life.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P273 Avoid release to the environment.

Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Response:

P391 Collect spillage.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|--------------------|--------------|-----------------------|
| Sodium chloride | 7647-14-5 | >= 5 - < 10 |
| Cellulose | 9004-34-6 | >= 5 - < 10 |
| Grazoprevir | 1350462-55-3 | >= 5 - < 10 |
| Elbasvir | 1370468-36-2 | >= 2.5 - < 5 |
| Magnesium stearate | 557-04-0 | >= 1 - < 5 |
| Titanium dioxide | 13463-67-7 | >= 0.1 - < 1 |

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

- Unsuitable extinguishing media : Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Metal oxides
Chlorine compounds
Nitrogen oxides (NO_x)
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
-

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Local/Total ventilation : Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Advice on safe handling : Use only with adequate ventilation.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage : Keep in properly labelled containers.
Store in accordance with the particular national regulations.
Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--------------------|--------------|-------------------------------------|--|----------|
| Cellulose | 9004-34-6 | TWA | 10 mg/m ³ | ACGIH |
| Grazoprevir | 1350462-55-3 | TWA | 85 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 850 µg/100 cm ² | Internal |
| Elbasvir | 1370468-36-2 | TWA | 150 µg/m ³ (OEB 2) | Internal |
| Magnesium stearate | 557-04-0 | TWA (Inhalable particulate matter) | 10 mg/m ³ | ACGIH |
| | | TWA (Respirable particulate matter) | 3 mg/m ³ | ACGIH |
| Titanium dioxide | 13463-67-7 | TWA (Respirable particulate matter) | 2.5 mg/m ³ (Titanium dioxide) | ACGIH |

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Minimize open handling.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
-

9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Colour : white
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable

Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

| | | |
|--|---|---|
| Evaporation rate | : | Not applicable |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | Not applicable |
| Relative vapour density | : | Not applicable |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity Viscosity, kinematic | : | Not applicable |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Particle size | : | No data available |

10. STABILITY AND REACTIVITY

| | | |
|------------------------------------|---|--|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents. |
| Conditions to avoid | : | Heat, flames and sparks. Avoid dust formation. |
| Incompatible materials | : | Oxidizing agents |
| Hazardous decomposition products | : | No hazardous decomposition products are known. |

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Sodium chloride:

Acute oral toxicity : LD50 (Rat): 3,550 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 42 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Grazoprevir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Elbasvir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 1,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Sodium chloride:

Species : Rabbit
Result : No skin irritation

Grazoprevir:

Result : No skin irritation

Elbasvir:

Species : reconstructed human epidermis (RhE)
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Sodium chloride:

Species : Rabbit
Result : No eye irritation

Grazoprevir:

Species : Bovine cornea
Result : No eye irritation

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Elbasvir:

Species : Bovine cornea
Result : No eye irritation

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Sodium chloride:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse
Result : negative

Grazoprevir:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Dermal
Result : Not a skin sensitizer.

Elbasvir:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Dermal
Species : Mouse
Result : negative

Magnesium stearate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Exposure routes : Skin contact
Species : Mouse
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Sodium chloride:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Saccharomyces cerevisiae, gene mutation assay (in vitro)
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive

Test Type: Chromosome aberration test in vitro
Result: positive

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Intraperitoneal injection
Result: positive

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)

Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Species: Mouse
Application Route: Ingestion
Result: negative

Grazoprevir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Elbasvir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Rat
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Sodium chloride:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Titanium dioxide:

Species : Rat
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : positive
Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

Reproductive toxicity

Not classified based on available information.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Grazoprevir:

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: negative

Test Type: Multi-generation study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: No effects on fertility, No effects on foetal development

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight
Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight
Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous
Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight
Result: No effects on foetal development

Elbasvir:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
Fertility: NOAEL: 1,000 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Grazoprevir:

Target Organs : Liver, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Sodium chloride:

Species : Rat
LOAEL : 2,533 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Cellulose:

Species : Rat
NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Grazoprevir:

Species : Rat
NOAEL : 400 mg/kg
Application Route : Oral
Exposure time : 30 Days
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 400 mg/kg
Application Route : Oral
Exposure time : 180 Days
Remarks : No significant adverse effects were reported

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Species : Dog
NOAEL : 15 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 270 Days
Target Organs : Liver, Blood, Bone marrow, gallbladder, spleen, Testis

Species : Mouse
NOAEL : 200 mg/kg
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 Days
Target Organs : Liver, Kidney, Blood

Species : Dog
NOAEL : 20 mg/kg
LOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 30 Days
Target Organs : Blood, Testis

Species : Monkey
NOAEL : 10 mg/kg
Exposure time : 8 Days
Remarks : No significant adverse effects were reported

Elbasvir:

Species : Rat
NOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 180 d
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 270 d
Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rat
NOAEL : 24,000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Species : Rat
NOAEL : 10 mg/m³
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 yr

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Grazoprevir:

Ingestion : Symptoms: Headache, Gastrointestinal disturbance

Elbasvir:

Ingestion : Symptoms: Headache, Abdominal pain, constipation, Nausea, Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irritation, rhinitis, Drowsiness, nasal congestion

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Sodium chloride:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 4,136 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50: > 2,000 mg/l
Exposure time: 96 h

Toxicity to microorganisms : EC10: > 1,000 mg/l

Toxicity to fish (Chronic toxicity) : NOEC: 252 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 314 mg/l
Exposure time: 21 d
Species: Daphnia pulex (Water flea)

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Grazoprevir:

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

LC50 (Americamysis): 8.9 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 0.98 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 5 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Elbasvir:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

LC50 (Menidia beryllina (Silverside)): > 10 mg/l
Exposure time: 96 h

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

LC50 (Americamysis): 7.7 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 271.9 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 0.0023 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.84 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 10

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other : EL50 (Daphnia magna (Water flea)): > 1 mg/l

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

- aquatic invertebrates Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility
- Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility
- NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
- Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Titanium dioxide:

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
- Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h
- Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Grazoprevir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 66 %

Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

Exposure time: 28 d

Elbasvir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 37 %
Exposure time: 28 d

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Grazoprevir:

Bioaccumulation : Species: *Lepomis macrochirus* (Bluegill sunfish)
Bioconcentration factor (BCF): 7.62

Partition coefficient: n-octanol/water : log Pow: 3.72

Elbasvir:

Bioaccumulation : Species: *Lepomis macrochirus* (Bluegill sunfish)
Bioconcentration factor (BCF): 82
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 6.54

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Grazoprevir:

Distribution among environmental compartments : log Koc: 4.01

Elbasvir:

Distribution among environmental compartments : log Koc: 5.24

Other adverse effects

No data available

Grazoprevir / Elbasvir Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 76520-00026 Date of last issue: 04.04.2023
Date of first issue: 17.03.2015

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Elbasvir)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Elbasvir)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Elbasvir)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 5.1 | 30.09.2023 | 76520-00026 | Date of first issue: 17.03.2015 |

Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

| | | |
|-------|---|----------------|
| AICS | : | not determined |
| DSL | : | not determined |
| IECSC | : | not determined |

16. OTHER INFORMATION

Revision Date : 30.09.2023

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances

SAFETY DATA SHEET

according to the Globally Harmonized System



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 5.1 | 30.09.2023 | 76520-00026 | Date of first issue: 17.03.2015 |

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN